ReviewJournal of medical ultrasonics (2001)2020
Advances in ultrasound elastography for nonalcoholic fatty liver disease.
Review in Journal of medical ultrasonics (2001), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis.Lipids in health and disease · 2023Pooled it
- NAFLD-related SNPs are linked to changes in liver fat, as measured by the CAP score, and serum lipids in response to a 3-week sugar-sweetened beverage intervention: a pilot study.Food & function · 2026Trial
- Correlation analysis and diagnostic performance of CT/MRI fat quantification parameters in metabolic dysfunction-associated steatotic liver disease.Frontiers in medicine · 2026Article
- Endo-hepatology: Bridging the gap between lumen and liver.World journal of gastroenterology · 2025Review
- Deep attenuation transducer to measure liver stiffness in obese patients with liver disease.Journal of medical ultrasonics (2001) · 2023Article
- Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease.Hepatology research : the official journal of the Japan Society of Hepatology · 2022Review
- Magnetic resonance elastography plus Fibrosis-4 versus FibroScan-aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis.Hepatology (Baltimore, Md.) · 2022Article
- Diagnostic performance of ultrasound attenuation imaging for assessing low-grade hepatic steatosis.European radiology · 2022Article
- Evaluation of ultrasonic fibrosis diagnostic system using convolutional network for ordinal regression.International journal of computer assisted radiology and surgery · 2021Article
- Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease.Journal of medical ultrasonics (2001) · 2021Review
- The FibroScan-aspartate aminotransferase score can stratify the disease severity in a Japanese cohort with fatty liver diseases.Scientific reports · 2021Article
- Validation of a two-step approach combining serum biomarkers and liver stiffness measurement to predict advanced fibrosis.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Diagnostic Accuracy of FibroScan and Factors Affecting Measurements.Diagnostics (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) has increased rapidly worldwide, making NAFLD/NASH an important global health problem from both a medical and socioeconomic standpoint. NAFLD is also regarded as a liver component of metabolic syndrome and is reported to be associated with the risk factors for metabolic syndrome. It has been suggested that NAFLD/NASH be recognized both as a liver-specific disease and as an early mediator of systemic diseases. Liver biopsy is recommended as the gold standard method for the diagnosis of NASH and for the staging of liver fibrosis in patients with NAFLD. However, because of its high cost, high risk, and high weightage as a healthcare resource, invasive liver biopsy is a poorly suited diagnostic test for such a highly prevalent condition. Therefore, the development of reliable noninvasive methods for the assessment of liver fibrosis has been sought to estimate the risk of progression of NASH to cirrhosis, estimate the risk of cardiovascular events, aid in the surveillance for HCC, and guide therapy in patients with NAFLD/NASH. In this review, we highlight the principles and recent advances in ultrasound elastography techniques (Real-time Tissue Elastography
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.